3d
Medpage Today on MSNAdjuvant Nivolumab Boosts Survival Outcomes in Muscle-Invasive Bladder CancerPost-surgical adjuvant nivolumab (Opdivo) improved survival outcomes in muscle-invasive bladder cancer (MIBC), regardless of ...
Nivolumab plus cabozantinib improved long-term efficacy and safety vs sunitinib in advanced renal cell carcinoma, per final ...
(HealthDay News) — For patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer (BC), adding nivolumab to ...
Tivozanib plus nivolumab had similar patient-reported outcomes to tivozanib alone in advanced kidney cancer after prior ...
Nivolumab plus cabozantinib provides long-term benefits over sunitinib in advanced RCC, according to final results from CheckMate 9ER.
Patients may require life-long monitoring and a collaborative engagement with subspecialists to keep well in the long -term,” ...
Opdualag is a fixed-dose combination of nivolumab, a programmed death receptor-1 blocking antibody, and relatlimab, a lymphocyte activation gene 3 blocking antibody.
Adjuvant nivolumab after radical surgery can improve DFS and OS in patients with MIBC, results from the CheckMate 274 trial suggest.
Patient-reported outcomes (PROs) were similar among those treated with tivozanib monotherapy and those given combination ...
Squibb announced the final analysis of overall survival, or OS, from the Phase 3 CheckMate -816 study, which evaluated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results